Adavosertib and Wee1 inhibitors (Zn-C3; Debio 0123; SY4835; and IMP7068) are promising in ALL and other cancers as single and drug combination therapy [4] as revealed by prior and ongoing clinical trials [4,9,10]. This evidence concerns the gene WEE1 and acute lymphoblastic leukemia.